scholarly journals Monoclonal antibodies in COVID-19 management: a scoping review

2021 ◽  
Vol 10 (10) ◽  
pp. 1215
Author(s):  
Umayal Adaikkalavan ◽  
Jeeja Mathummal Cherumanalil ◽  
Salwa Pannikkottuthodi ◽  
Hasna Poovancheri
Keyword(s):  
Monoclonal Antibodies ◽  
Scoping Review ◽  
Adverse Reactions ◽  
Therapeutic Agents ◽  
World Health ◽  
Effective Control ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
The World ◽  
Health Organization

Coronavirus disease 2019 (COVID-19) was declared as pandemic on March 11th 2020 by the world health organization (WHO). Vaccination is for preventing COVID-19 morbidity but when people are infected, treatment is required and even after one and half years the effective cure is yet to be discovered. In this context monoclonal antibodies (mAbs) are promising innovative therapeutic agents in controlling COVID-19 infection. Researchers have found more than 50 mAbs against COVID-19 and they are at different stages of development.  Scientists are pacing the research on mAbs. mAbs are innovative therapeutic agents in this context a scoping narrative review was done. At present we have evidences from numerous randomized controlled trials (RCT) on mAbs in effective control of respiratory and coagulation related complications due to COVID-19 infection. Many have got emergency use approval and few of which were withdrawn due to absence of enough evidences or adverse reactions. Examples are bamlanivimab, etesevimab, casirivimab and imdevimab. Other than these many investigational (mAbs) are under scrutiny. With the current evidences the article will give an insight to new and repurposed mAbs which are still under investigation in the management of COVID-19 infections.

Characterizing the effectiveness of COVID-19 mitigation measures: A data-centric approach (Preprint)

2020 ◽  
Author(s):  
Lukman Olagoke ◽  
Ahmet E. Topcu
Keyword(s):  
Control Measure ◽  
Control Measures ◽  
World Health ◽  
Mitigation Measures ◽  
Effective Control ◽  
The World ◽  
Decision Making Processes ◽  
And Performance ◽  
Health Organization ◽  
The Impact

BACKGROUND COVID-19 represents a serious threat to both national health and economic systems. To curb this pandemic, the World Health Organization (WHO) issued a series of COVID-19 public safety guidelines. Different countries around the world initiated different measures in line with the WHO guidelines to mitigate and investigate the spread of COVID-19 in their territories. OBJECTIVE The aim of this paper is to quantitatively evaluate the effectiveness of these control measures using a data-centric approach. METHODS We begin with a simple text analysis of coronavirus-related articles and show that reports on similar outbreaks in the past strongly proposed similar control measures. This reaffirms the fact that these control measures are in order. Subsequently, we propose a simple performance statistic that quantifies general performance and performance under the different measures that were initiated. A density based clustering of based on performance statistic was carried out to group countries based on performance. RESULTS The performance statistic helps evaluate quantitatively the impact of COVID-19 control measures. Countries tend show variability in performance under different control measures. The performance statistic has negative correlation with cases of death which is a useful characteristics for COVID-19 control measure performance analysis. A web-based time-line visualization that enables comparison of performances and cases across continents and subregions is presented. CONCLUSIONS The performance metric is relevant for the analysis of the impact of COVID-19 control measures. This can help caregivers and policymakers identify effective control measures and reduce cases of death due to COVID-19. The interactive web visualizer provides easily digested and quick feedback to augment decision-making processes in the COVID-19 response measures evaluation. CLINICALTRIAL Not Applicable

scholarly journals Osteopathic correction in the treatment of pain in the lower back

2020 ◽  
pp. 140-146
Author(s):  
V. O. Belash ◽  
Yu. O. Novikov
Keyword(s):  
Back Pain ◽  
Developed Countries ◽  
Economic Problem ◽  
World Health ◽  
Randomized Controlled ◽  
Lower Back ◽  
The World ◽  
Working Age ◽  
Acute Back Pain ◽  
Health Organization

According to experts of the World Health Organization the lower back pain (LBP) prevalence in developed countries reaches the pandemic size, and it is a serious medical and socio-economic problem. Acute back pain is transformed into chronic in 10–20 % of working age patients′ cases; this causes serious psychological disorders appearing, forms painful behavior and persists even when the initial pain trigger is eliminated. Data from metaanalyses of randomized controlled trials indicate the effectiveness of the osteopathic approach in the treatment of LBP patients. At the same time the osteopathic correction is effective not only for acute pain, but also for chronic pain. A case from clinical practice is described demonstrating the possibility of osteopathic correction of a LBP patient.

scholarly journals Rehabilitation Care at the Time of Coronavirus Disease-19 (COVID-19) Pandemic: A Scoping Review of Health System Recommendations

2022 ◽  
Vol 13 ◽  
Author(s):  
Ahmed M. Negm ◽  
Adrian Salopek ◽  
Mashal Zaide ◽  
Victoria J. Meng ◽  
Carlos Prada ◽  
...  
Keyword(s):  
Scoping Review ◽  
Full Text ◽  
Data Extraction ◽  
Health Care Systems ◽  
Social Systems ◽  
World Health ◽  
Rehabilitation Services ◽  
Rehabilitation Care ◽  
The World ◽  
Health Organization

Purpose: The coronavirus disease-19 (COVID-19) was declared a pandemic by the World Health Organization in March 2020. COVID-19, caused by SARS-CoV-2 has imposed a significant burden on health care systems, economies, and social systems in many countries around the world. The provision of rehabilitation services for persons with active COVID-19 infection poses challenges to maintaining a safe environment for patients and treating providers.Materials and Methods: Established frameworks were used to guide the scoping review methodology. Medline, Embase, Pubmed, CINAHL databases from inception to August 1, 2020, and prominent rehabilitation organizations’ websites were searched.Study Selection: We included articles and reports if they were focused on rehabilitation related recommendations for COVID-19 patients, treating providers, or the general population.Data Extraction: Pairs of team members used a pre-tested data abstraction form to extract data from included full-text articles. The strength and the quality of the extracted recommendations were evaluated by two reviewers using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach.Results: We retrieved 6,468 citations, of which 2,086 were eligible for review, after duplicates were removed. We excluded 1,980 citations based on title and abstract screening. Of the screened full-text articles, we included all 106 studies. A summary of recommendations is presented. We assessed the overall evidence to be strong and of fair quality.Conclusion: The rehabilitation setting, and processes, logistics, and patient and healthcare provider precaution recommendations identified aim to reduce the spread of SARS-CoV-2 infection and ensure adequate and safe rehabilitation services, whether face-to-face or through teleservices. The COVID-19 pandemic is rapidly changing. Further updates will be needed over time in order to incorporate emerging best evidence into rehabilitation guidelines.

scholarly journals The efficacy and safety of interferons for the treatment of patients with COVID-19: protocol for systematic review and meta-analysis of controlled trials

2021 ◽  
Author(s):  
Afsaneh Noormandi ◽  
Mohammad Fathalipour ◽  
Reza Daryabeygi-Khotbehsara ◽  
Soheil Hassanipour
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Meta Analysis ◽  
World Health ◽  
Controlled Trials ◽  
Efficacy And Safety ◽  
Global Pandemic ◽  
The World ◽  
Health Organization ◽  
Time Of Administration

Background and objective: COVID-19 has since been declared a global pandemic by the World Health Organization (WHO), infecting millions worldwide. The use of Interferon (INF) subtypes previously examined in the treatment of SARS and MERS is also being initiated in some clinical trials. Although different clinical trials were evaluated IFNs in the treatment of COVID-19, their efficacy and safety remain unknown. Therefore, this study aims to systematically assess IFNs efficacy and safety in treating patients with COVID-19. Methods: The protocol has been registered in the PROSPERO International Prospective Register (CRD42020200643) on 24 July 2020. This protocol has been arranged according to the PRISMA-P (Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols) 2015 checklist. Discussion: Due to lack of approved medication for the covid-19 treatment and also various mutations of this virus, evaluated the efficacy and safety of medications by various studies could help for finding treatments with high effectiveness. IFNs are one of the medications that have been administered in covid-19 infection.  Moreover, the best time of administration and dose of this medication was unknown. Although meta-analysis is a potent source for assessing the accuracy of subjects, heterogeneity of articles is a potent limitation of our work.

scholarly journals Antiplasmodial natural products: an update

2019 ◽  
Vol 18 (1) ◽  
Author(s):  
Nasir Tajuddeen ◽  
Fanie R. Van Heerden
Keyword(s):  
Natural Products ◽  
Relevant Literature ◽  
World Health ◽  
Effective Control ◽  
Insecticide Treated Nets ◽  
Scientific Databases ◽  
The World ◽  
Significant Public Health ◽  
Public Health Challenge ◽  
Health Organization

Abstract Background Malaria remains a significant public health challenge in regions of the world where it is endemic. An unprecedented decline in malaria incidences was recorded during the last decade due to the availability of effective control interventions, such as the deployment of artemisinin-based combination therapy and insecticide-treated nets. However, according to the World Health Organization, malaria is staging a comeback, in part due to the development of drug resistance. Therefore, there is an urgent need to discover new anti-malarial drugs. This article reviews the literature on natural products with antiplasmodial activity that was reported between 2010 and 2017. Methods Relevant literature was sourced by searching the major scientific databases, including Web of Science, ScienceDirect, Scopus, SciFinder, Pubmed, and Google Scholar, using appropriate keyword combinations. Results and Discussion A total of 1524 compounds from 397 relevant references, assayed against at least one strain of Plasmodium, were reported in the period under review. Out of these, 39% were described as new natural products, and 29% of the compounds had IC50 ≤ 3.0 µM against at least one strain of Plasmodium. Several of these compounds have the potential to be developed into viable anti-malarial drugs. Also, some of these compounds could play a role in malaria eradication by targeting gametocytes. However, the research into natural products with potential for blocking the transmission of malaria is still in its infancy stage and needs to be vigorously pursued.

scholarly journals COVID-19 Drug Discovery Using Intensive Approaches

2020 ◽  
Vol 21 (8) ◽  
pp. 2839 ◽  
Author(s):  
Ayumu Asai ◽  
Masamitsu Konno ◽  
Miyuki Ozaki ◽  
Chihiro Otsuka ◽  
Andrea Vecchione ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Rna Viruses ◽  
Drug Repurposing ◽  
Global Scale ◽  
Therapeutic Agents ◽  
Clinical Development ◽  
World Health ◽  
Antiviral Therapies ◽  
The World ◽  
Health Organization

Since the infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in China during December 2019, the coronavirus disease 2019 (COVID-19) has spread on a global scale, causing the World Health Organization (WHO) to issue a warning. While novel vaccines and drugs that target SARS-CoV-2 are under development, this review provides information on therapeutics which are under clinical trials or are proposed to antagonize SARS-CoV-2. Based on the information gained from the responses to other RNA coronaviruses, including the strains that cause severe acute respiratory syndrome (SARS)-coronaviruses and Middle East respiratory syndrome (MERS), drug repurposing might be a viable strategy. Since several antiviral therapies can inhibit viral replication cycles or relieve symptoms, mechanisms unique to RNA viruses will be important for the clinical development of antivirals against SARS-CoV-2. Given that several currently marketed drugs may be efficient therapeutic agents for severe COVID-19 cases, they may be beneficial for future viral pandemics and other infections caused by RNA viruses when standard treatments are unavailable.

scholarly journals Cheese, Microbiome and Obesity: A Love Triangle

2021 ◽  
Author(s):  
Jeremy Meyer ◽  
Elin Roos ◽  
Jacques Schrenzel ◽  
Frédéric Ris ◽  
Justin Davies
Keyword(s):  
European Countries ◽  
World Health ◽  
Dairy Food ◽  
Randomized Controlled ◽  
Dairy Consumption ◽  
The World ◽  
Prevalence Of Obesity ◽  
Per Capita ◽  
Health Organization ◽  
Love Triangle

Abstract IntroductionRecent evidence has shown the importance of the microbiome in the development and maintenance of obesity. Probiotics were proposed for modulating the microbiome in order to achieve weight loss.MethodsData related to consumption of dairy food in European countries were obtained from the Global Dairy Consumption Report of the European Association of Dairy Trade Eucolait. Age-adjusted prevalence of obesity in European countries was extracted from the World Health Organization Global Health Repository. Linear regression was performed.ResultsConsumption of cheese in kilogram per capita was inversely correlated to the age-adjusted prevalence of obesity in 26 European countries (R2: 0.298, p=0.004).ConclusionConsumption of cheese appears to protect against weight gain. This finding deserves further confirmation by longitudinal studies or randomized controlled trials.

scholarly journals A Review of Registered Randomized Controlled Trials for the Prevention of Obesity in Infancy

2020 ◽  
Author(s):  
Seema Mihrshahi ◽  
Danielle Jawad ◽  
Louise A. Richards ◽  
Kylie Hunter ◽  
Mahalakshmi Ekambareshwar ◽  
...  
Keyword(s):  
Randomized Controlled Trials ◽  
Overweight And Obesity ◽  
World Health ◽  
Public Health Issue ◽  
Published Data ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Child Weight ◽  
Health Organization

Childhood overweight and obesity is a worldwide public health issue. Our objective was to describe planned, ongoing and completed randomized controlled trials (RCTs) designed for the prevention of obesity in early childhood. Two databases (World Health Organization International Clinical Trials Registry Platform, ClinicalTrials.gov) were searched to identify RCTs with the primary aim of preventing childhood obesity and at least one outcome related to child weight. Interventions needed to start in the first two years of childhood or earlier, continue for at least 6 months postnatally, include a component related to lifestyle or behaviors, and have a follow up time of at least 2 years. We identified 29 unique RCTs, implemented since 2008, with most being undertaken in high income countries. Interventions ranged from advice on diet, activity, sleep, emotion regulation and parenting education through individual home visits, clinic-based consultations or group education sessions. Eleven trials have published data on child weight related outcomes to date, though most were not sufficiently powered to detect significant effects. Many trials detected improvements in practices such as breastfeeding, screen time and physical activity in the intervention groups compared to the control groups. Further follow-up of ongoing trials is needed to assess longer-term effects.

Sign in / Sign up

Export Citation Format

Share Document